InvestorsHub Logo
Followers 65
Posts 40017
Boards Moderated 2
Alias Born 07/08/2002

Re: None

Tuesday, 12/05/2017 10:44:44 AM

Tuesday, December 05, 2017 10:44:44 AM

Post# of 8426
ROCKVILLE, Md., Dec. 5, 2017 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that Steve Shallcross, the Company's Chief Financial Officer, has been named interim CEO to succeed Jeff Riley, who has resigned as an officer and director of the Company, effective immediately, for personal reasons.

Synthetic Biologics, Inc. www.syntheticbiologics.com (PRNewsFoto/Synthetic Biologics, Inc.)

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent TOVX News